secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2023-04-05T23:59:59+00:00
Accession:  0000950170-23-011915
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen appoints Eric Bjerkholt as Class I director and audit committee member
-------------------------------------------------------------------------------

- Eric Bjerkholt appointed to board as Class I director effective April 5, 2023.
- He will serve on the audit committee.
- Bjerkholt is CFO of Chinook Therapeutics; previously CFO of Aimmune, leading its $2.6B sale to Nestle.
- Compensation: $35,000 annual retainer, $7,500 audit retainer, initial option grant of 40,000 shares vesting over 36 months.
- Standard indemnification agreement entered with Bjerkholt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017023011915/0000950170-23-011915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017023011915/srzn-20230405.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-011915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer